Immuron IMRN
NASDAQ IMRN
$1.77 -0.07 (-3.80%)
As of: Sep 9, 2026 · 3:59 PM EDT

Immuron (IMRN) Non Operating Interest Expenses (2017 - 2025)

Immuron (IMRN) posted Non Operating Interest Expenses of -$4678.4 for Q2 2025, down 9167.48% on a QoQ basis from -$50.48 in Q3 2024, and up 6.3% year-over-year from -$4401.2 in Q2 2024.

Analysis

Immuron (IMRN) Non Operating Interest Expenses (2017 - 2025) Analysis & Trends

Immuron has reported Non Operating Interest Expenses for 8 years, with the latest figure at -$4678.4 in Q2 2025.

  • On a quarterly basis, Non Operating Interest Expenses rose 6.3% year-over-year to -$4678.4 in Q2 2025; TTM through Jun 2025 was -$16005.0, a 135.9% decrease from a year earlier, with the FY2026 full-year figure at -$14712.0, down 20039.63% from the prior year.
  • Non Operating Interest Expenses was -$4678.4 for Q2 2025 at Immuron, down from -$50.48 in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was $4501.0 in Q4 2022, with the low at -$10596.7 in Q2 2021.
  • Average Non Operating Interest Expenses over 5 years is -$3158.6, with a median of -$4678.4 recorded in 2025.
  • The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses surged 47253.03% in 2022, then plunged 239.6% in 2023.
  • Over 5 years, Non Operating Interest Expenses stood at -$9.55 in 2021, then soared by 47253.03% to $4501.0 in 2022, then slumped by 239.6% to -$6283.4 in 2023, then jumped by 99.2% to -$50.48 in 2024, then plunged by 9167.48% to -$4678.4 in 2025.
  • The last three Non Operating Interest Expenses figures came in at -$4678.4 (Q2 2025), -$50.48 (Q3 2024), and -$4992.8 (Q2 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Immuron 10.28 Mn 1.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -4,678.36
Sep 9, 2024 -50.48
Jun 30, 2024 -4,992.77
Dec 31, 2023 -6,283.36
Dec 31, 2022 4,501.00
Dec 31, 2021 -9.55
Jun 30, 2021 -10,596.73
Dec 31, 2020 -58.04
Jun 30, 2020 -14,177.40
Dec 31, 2019 -23.46
Dec 31, 2017 -2,896.97